The evolution of breast cancer care is increasingly challenging a long-standing assumption in oncology: that greater treatment intensity necessarily translates into better outcomes.

For carefully selected patients, emerging evidence supports a different approach. Advances in molecular profiling, genomic assays, imaging and response assessment are allowing multidisciplinary teams to identify circumstances in which chemotherapy can be omitted, systemic regimens shortened, or breast and axillary surgery reduced without compromising oncologic goals.

The concept, broadly described as treatment de-escalation, reflects the continued transition from stage-driven treatment toward increasingly biology- and response-driven care.

“De-escalation of treatment involves a change in paradigm from ‘more is better’ to ‘the right treatment for the right patient,’” says Zdenka Ena Segota, M.D., hematologist oncologist with Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital. “It aims at improving cancer outcomes by avoiding excessive toxicity and side effects.”

The key qualifier is patient selection. De-escalation is not synonymous with undertreatment, nor is it appropriate across breast cancer subtypes. Rather, the objective is to identify therapies that meaningfully contribute to disease control and survival for an individual patient while avoiding interventions whose incremental benefit may not justify their associated toxicity or morbidity.

Moving Beyond Anatomy Alone

Tumor size, stage and nodal status remain central to treatment planning, but they are no longer sufficient to characterize the clinical behavior of an individual breast cancer.

Hormone receptor and HER2 status, genomic assays and response to neoadjuvant therapy increasingly inform decisions about systemic treatment intensity.

“There is an increasing realization that breast cancers are not equal when it comes to aggressiveness, and some can be managed successfully without the need for maximum therapy,” Dr. Segota says.

For medical oncologists, one of the clearest examples is early-stage hormone receptor-positive, HER2-negative breast cancer. Genomic assays such as Oncotype DX, MammaPrint and PAM50 can help estimate recurrence risk and, in appropriate clinical settings, inform the expected benefit of chemotherapy.

As a result, some patients who historically may have received adjuvant chemotherapy can now safely avoid it based on a combination of genomic and clinicopathologic factors.

“Patient selection is critical,” Dr. Segota says. “We evaluate several factors, including tumor size and stage, lymph node involvement, hormone receptor and HER2 status, genomic assay results such as Oncotype DX, MammaPrint, or PAM50; patient age and overall health, response to neoadjuvant therapy.”

Testing De-Escalation in More Aggressive Disease

The de-escalation paradigm is also being investigated in breast cancer subtypes traditionally associated with more intensive systemic therapy.

Dr. Segota points to SWOG S2212, or SCARLET, an ongoing clinical trial evaluating whether patients with early-stage triple-negative breast cancer can safely receive a shorter, anthracycline-free chemo-immunotherapy regimen.

The question reflects the next phase of de-escalation research: whether treatment intensity can be reduced not simply in favorable-risk disease, but in selected patients with biologically aggressive cancers when therapeutic response or other factors indicate that a modified regimen may be sufficient.

Such studies are particularly relevant as effective systemic treatment options expand. The central question increasingly becomes not only which therapy works, but which components and duration of therapy are necessary to preserve benefit.

Biomarkers and Response-Adapted Treatment

Biomarkers are central to this evolution because they provide information beyond traditional anatomic staging.

“Biomarkers allow us to better understand the biology of an individual tumor rather than relying solely on anatomic features,” Dr. Segota says.

Genomic assays can help quantify recurrence risk and predict chemotherapy benefit in hormone receptor-positive disease. Response to neoadjuvant therapy provides another potentially powerful source of prognostic information.

In particular, pathologic complete response (pCR) following neoadjuvant therapy is associated with favorable long-term outcomes and may help identify patients who could be candidates for less intensive subsequent therapy in selected clinical settings.

This creates the potential for an increasingly dynamic treatment model: Rather than determining the entire therapeutic course at diagnosis, clinicians can incorporate the tumor’s observed response to treatment into subsequent decisions.

Neoadjuvant Therapy Is Also Changing Surgical Options

Response-adapted treatment has important implications for surgery.

Hilary Shapiro-Wright, D.O., breast surgical oncologist at the Eugene M. & Christine E. Lynn Cancer Institute and Christine E. Lynn Women’s Health & Wellness Institute, part of Baptist Health, at Boca Raton Regional Hospital. describes surgical de-escalation as minimizing the extent of an operation while maintaining the same oncologic goals.

“Surgeons can avoid unnecessary procedures and still fully treat a patient’s breast cancer while reducing risk,” Dr. Shapiro-Wright says.

The expanding use of neoadjuvant systemic therapy has created additional opportunities to reduce surgical morbidity. For appropriate patients, chemotherapy, immunotherapy or anti-estrogen therapy administered before surgery can downstage the primary tumor, potentially converting a patient from mastectomy to breast-conserving surgery.

Response within initially involved axillary nodes can similarly alter the surgical approach.

Patients who demonstrate an appropriate nodal response may be candidates for less extensive axillary surgery, reducing the number of lymph nodes removed and potentially decreasing the risk of lymphedema, chronic pain and impaired upper-extremity range of motion.

Reconsidering the Extent of Breast and Axillary Surgery

Surgical de-escalation is not limited to response after systemic therapy.

Improved imaging and image-guided biopsy techniques are providing increasingly precise assessments of disease extent before an operation. Mammography, ultrasound, contrast-enhanced mammography and breast MRI can all contribute to surgical planning.

“Advances in imaging, biopsy techniques and identification of tumor biology are all helping surgeons determine when patients may be a good candidate for breast-conserving surgery and also de-escalation of surgical evaluation of axillary lymph nodes,” Dr. Shapiro-Wright says.

For example, selected patients with multiple ipsilateral breast tumors may be candidates for breast conservation rather than mastectomy. Similarly, some patients with lower-risk, early-stage disease may safely avoid certain axillary staging procedures.

The rationale is not simply to make an operation smaller. Reducing unnecessary surgery may decrease pain, cosmetic changes, lymphedema and other complications without sacrificing the therapeutic objective.

“Less surgery decreases morbidity and complications, including things like pain, cosmetic changes and lymphedema of the upper extremity, allowing patients improved quality of life along with less surgical risks,” Dr. Shapiro-Wright says.

Addressing the Perception That More Surgery Is Safer

Even when clinical evidence supports de-escalation, implementation requires addressing how patients perceive risk.

This is particularly relevant when discussing breast conservation versus mastectomy. Some patients may interpret the more extensive procedure as providing greater protection from recurrence or improved survival.

For appropriately selected patients, however, breast-conserving surgery with radiation and mastectomy have demonstrated comparable overall survival, and mastectomy does not eliminate the possibility of recurrence.

“I believe that the fear of recurrence is the fear of uncertainty, and this can lead patients to choose more surgery than is needed to accomplish the same treatment goals,” Dr. Shapiro-Wright says. “It is important as a breast surgeon to validate those fears while at the same time providing the education and support to patients.”

The conversation therefore extends beyond technical eligibility for de-escalation. Clinicians must communicate absolute benefit, recurrence risk, potential toxicity and treatment morbidity in a way that allows patients to understand why a less extensive intervention may still represent appropriate cancer treatment.

Shared Decision-Making Becomes More Important as Options Expand

The increasing personalization of treatment also makes multidisciplinary and shared decision-making more consequential.

For medical oncology, discussions may include the expected absolute benefit of chemotherapy or another systemic therapy, genomic risk estimates, toxicity and available clinical trial data. Surgical discussions may incorporate oncologic safety, recovery, complications, cosmetic outcomes and patient preferences.

“That concern is understandable,” Dr. Segota says of patients who worry that less treatment may mean accepting greater risk. “We review the patient’s individual risk factors, discuss relevant clinical trial data, and explain the expected absolute benefit of each treatment option.”

For surgeons, the decision similarly extends beyond technical feasibility.

“Surgery is not a one-size-fits-all approach,” Dr. Shapiro-Wright says. “Each patient should balance their disease, surgical goals and psychosocial factors when choosing which surgery is right for them.”

These conversations may involve breast surgery, medical oncology, radiation oncology, genetics and other disciplines, depending on the clinical scenario.

The Next Frontier: Identifying What Can Safely Be Omitted

Breast cancer de-escalation remains an evolving field, and the central challenge is defining the boundary between avoiding unnecessary treatment and undertreating disease.

Some breast cancers will continue to require intensive multimodality therapy.

“De-escalation is not the right strategy in all cases,” Dr. Segota says. “Some types of breast cancers will need intensive treatment to increase the chances of a cure.”

At the same time, ongoing studies are asking progressively more specific questions about what can safely be reduced or omitted.

Dr. Shapiro-Wright points to research examining whether selected patients with noninvasive breast cancer may eventually be able to omit surgery, while advances in imaging, minimally invasive surgical techniques and systemic therapies continue to expand opportunities for more individualized treatment.

For physicians, the emerging de-escalation paradigm therefore represents more than simply “less treatment.” It requires greater precision in selecting patients, interpreting tumor biology and assessing therapeutic response — supported by clinical evidence and multidisciplinary decision-making.

“Thanks to the advances in molecular testing and evaluation of response to the treatment,” Dr. Segota says, “we are able to tailor treatments now more accurately than ever before.”